Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Endocrinology · Pituitary adenoma

Mapping the Tumor: Blood, Scans, and Pathology

At a Glance

Diagnosing an AIP-mutated pituitary tumor requires more than one test: doctors combine hormone levels, pituitary-protocol MRI, visual field testing when needed, and pathology after surgery to understand the tumor and plan monitoring or treatment.

The process of diagnosing an AIP-mutated pituitary tumor involves three main pillars: biochemical testing (blood work), detailed imaging, and—if surgery is performed—a deep look at the tumor tissue under a microscope. Because these tumors can be more persistent than others, the goal of diagnosis is to create a complete “fingerprint” of the tumor to guide your long-term care [1][2].

Biochemical Testing: Reading the Hormones

Blood tests measure how much hormone the tumor is producing, but they also evaluate if the tumor is compressing the healthy gland and causing life-threatening deficiencies. While the focus in AIP cases is often on growth hormone and prolactin [3], a complete initial evaluation must also address morning cortisol/ACTH, free T4/TSH, gonadal function, and electrolytes to ensure your pituitary axes are safe.

  • Growth Hormone (GH) and IGF-1: Measuring GH directly can be tricky because it “pulses” throughout the day. Instead, doctors first test for IGF-1 (Insulin-like Growth Factor 1), which stays stable and acts as a marker for average GH levels [4]. If IGF-1 is high, you will likely undergo an Oral Glucose Tolerance Test (OGTT) [5]. You drink a sugary solution, and your GH is measured over several hours. In a healthy person, sugar shuts down GH production; if it doesn’t, this failure to suppress supports the biochemical diagnosis of GH excess [5][6].
  • Prolactin and the “Hook Effect”: Some tumors produce massive amounts of prolactin. Paradoxically, if the level is too high, some lab tests can get “overwhelmed” and report a falsely low number [7]. If you have a large tumor but your prolactin levels look surprisingly normal, your doctor should ask the lab to perform a dilution test to find the true value [3].

Imaging: The Pituitary-Protocol MRI

A standard brain MRI is not enough. You need a dedicated pituitary-protocol MRI, which uses thinner “slices” and special contrast dyes to see the tiny structures around the gland [8][9].

  • Optic Chiasm: The MRI checks if the tumor is pushing upward against the optic chiasm (where your eye nerves cross) [10].
  • Cavernous Sinus: It also looks at whether the tumor is growing sideways into the cavernous sinus, a space that houses major blood vessels and nerves that move your eyes [11].
  • Visual Field Testing: If the MRI shows the tumor is touching your optic nerves, you will need a formal visual field test [12]. You will sit in front of a machine and click a button when you see lights flash in your peripheral vision. This helps determine if the tumor is quietly reducing your side vision [12][13].

Pathology: The Tumor’s Fingerprint

If the tumor is removed, a pathologist will study it. Their report provides the final piece of the puzzle.

  • Lineage Markers: Stains for transcription factors tell the doctor which “family” of cells the tumor came from [14]. PIT1 indicates a lineage that can include GH-, prolactin-, and TSH-producing or clinically silent tumors, while TPIT or SF1 point to other cell types [14][15].
  • Ki-67 (Proliferation Index): This measures what percentage of cells are actively dividing [14]. There is no single reliable cutoff for an individual tumor, but some older classifications used a Ki-67 score higher than 3% to 5% alongside invasion and other factors to assess aggressiveness [16][17].
  • Mitotic Count: Similar to Ki-67, this counts how many cells are caught in the act of dividing [16].

Putting It All Together

Your diagnosis isn’t just one test result; it’s the combination of your AIP genetic status, your hormone levels, the MRI findings, and the pathology markers [1]. By bringing these together, your medical team can decide if you need a “watch and wait” approach or a more proactive treatment plan to keep the tumor controlled [18][19].

Common questions in this guide

Which hormone tests are part of an AIP pituitary tumor evaluation?
The evaluation commonly includes IGF-1 and, when appropriate, an oral glucose tolerance test to look for excess growth hormone. It also checks prolactin, morning cortisol and ACTH, free T4 and TSH, gonadal function, and electrolytes to look for other pituitary problems.
Why might a very large pituitary tumor need a diluted prolactin test?
A very high prolactin level can overwhelm some laboratory tests and produce a falsely low result, a problem called the hook effect. Diluting the blood sample can help the laboratory measure the true prolactin level.
What does a pituitary-protocol MRI look for?
A pituitary-protocol MRI uses thin images and contrast to show whether the tumor is pressing on the optic chiasm or extending into the cavernous sinus, where major blood vessels and nerves lie. If the tumor is near the optic nerves, formal visual field testing may check for loss of side vision.
What do PIT1, TPIT, SF1, Ki-67, and mitotic count tell doctors?
PIT1, TPIT, and SF1 are transcription-factor stains that help identify the tumor’s cell lineage. Ki-67 estimates the percentage of cells actively dividing, while the mitotic count records cells caught dividing. No single Ki-67 cutoff reliably predicts behavior for every tumor, so doctors interpret it with invasion and other findings.
How are AIP genetic results used with MRI and pathology findings?
AIP status is interpreted alongside hormone results, MRI findings, and pathology rather than used alone. Together, these findings help the medical team decide whether monitoring or more proactive treatment is appropriate and how often follow-up scans may be needed.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on pituitary adenoma 3, multiple types.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Did my prolactin test include a 'dilution' or 'hook effect' check to make sure the result isn't falsely low?
  2. 2.Based on the MRI, is my tumor touching the optic chiasm or growing into the cavernous sinus?
  3. 3.What was the Ki-67 percentage in my pathology report, and does it suggest a more active growth pattern?
  4. 4.Which transcription factors (PIT1, TPIT, or SF1) did my tumor express, and what does that tell us about its 'lineage'?
  5. 5.How do we combine my genetic results with these pathology markers to decide how often I need follow-up scans?

References

References (19)
  1. 1

    Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors.

    Marques P, Caimari F, Hernández-Ramírez LC, et al.

    The Journal of clinical endocrinology and metabolism 2020; (105(6)) doi:10.1210/clinem/dgaa040.

    PMID: 31996917
  2. 2

    Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers.

    Hernández-Ramírez LC, Gabrovska P, Dénes J, et al.

    The Journal of clinical endocrinology and metabolism 2015; (100(9)):E1242-54 doi:10.1210/jc.2015-1869.

    PMID: 26186299
  3. 3

    AIP variant causing familial prolactinoma.

    Carty DM, Harte R, Drummond RS, et al.

    Pituitary 2021; (24(1)):48-52 doi:10.1007/s11102-020-01085-5.

    PMID: 33010004
  4. 4

    Acromegaly.

    Dineen R, Stewart PM, Sherlock M

    QJM : monthly journal of the Association of Physicians 2017; (110(7)):411-420 doi:10.1093/qjmed/hcw004.

    PMID: 26873451
  5. 5

    Diagnosis and Treatment of Acromegaly: An Update.

    Ershadinia N, Tritos NA

    Mayo Clinic proceedings 2022; (97(2)):333-346 doi:10.1016/j.mayocp.2021.11.007.

    PMID: 35120696
  6. 6

    60 YEARS OF NEUROENDOCRINOLOGY: Acromegaly.

    Capatina C, Wass JA

    The Journal of endocrinology 2015; (226(2)):T141-60 doi:10.1530/JOE-15-0109.

    PMID: 26136383
  7. 7

    A novel pathogenic AIP variant associated with familial isolated pituitary adenoma.

    Marino Picciola V, Crociara A, Piacentini S, et al.

    Pituitary 2026; (29(3)).

    PMID: 42008033
  8. 8

    Modern imaging of pituitary adenomas.

    Bashari WA, Senanayake R, Fernández-Pombo A, et al.

    Best practice & research. Clinical endocrinology & metabolism 2019; (33(2)):101278 doi:10.1016/j.beem.2019.05.002.

    PMID: 31208872
  9. 9

    Thin-Slice Pituitary MRI with Deep Learning-based Reconstruction: Diagnostic Performance in a Postoperative Setting.

    Kim M, Kim HS, Kim HJ, et al.

    Radiology 2021; (298(1)):114-122 doi:10.1148/radiol.2020200723.

    PMID: 33141001
  10. 10

    Development and Evaluation of Deep Learning-based Automated Segmentation of Pituitary Adenoma in Clinical Task.

    Wang H, Zhang W, Li S, et al.

    The Journal of clinical endocrinology and metabolism 2021; (106(9)):2535-2546 doi:10.1210/clinem/dgab371.

    PMID: 34060609
  11. 11

    Cavernous Sinus Invasion in Pituitary Adenomas: Systematic Review and Pooled Data Meta-Analysis of Radiologic Criteria and Comparison of Endoscopic and Microscopic Surgery.

    Dhandapani S, Singh H, Negm HM, et al.

    World neurosurgery 2016; (96()):36-46 doi:10.1016/j.wneu.2016.08.088.

    PMID: 27591098
  12. 12

    Clinical characteristics and ophthalmologic findings of pituitary adenoma in Korean patients.

    Kim TG, Jin KH, Kang J

    International ophthalmology 2019; (39(1)):21-31 doi:10.1007/s10792-017-0778-x.

    PMID: 29274021
  13. 13

    The efficacy of microperimetry and contrast sensitivity test in the diagnosis of optic chiasm compression due to pituitary adenomas.

    Sarnat-Kucharczyk M, Kos-Kudła B, Kajdaniuk D, Mrukwa-Kominek E

    Endokrynologia Polska 2019; (70(3)):241-247 doi:10.5603/EP.a2019.0003.

    PMID: 30699232
  14. 14

    Clinical Implications of the New WHO Classification 2017 for Pituitary Tumors.

    Saeger W, Koch A

    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2021; (129(3)):146-156 doi:10.1055/a-1310-7900.

    PMID: 33690870
  15. 15

    Overview of the 2022 WHO Classification of Pituitary Adenomas/Pituitary Neuroendocrine Tumors: Clinical Practices, Controversies, and Perspectives.

    Wan XY, Chen J, Wang JW, et al.

    Current medical science 2022; (42(6)):1111-1118 doi:10.1007/s11596-022-2673-6.

    PMID: 36544040
  16. 16

    Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications.

    Miermeister CP, Petersenn S, Buchfelder M, et al.

    Acta neuropathologica communications 2015; (3()):50 doi:10.1186/s40478-015-0229-8.

    PMID: 26285571
  17. 17

    Aggressive Pituitary Adenoma Not Fulfilling the New High-Risk Criteria with Progression after 18-Year Stable Clinical Course: Case Report.

    Kawaguchi T, Ogawa Y, Watanabe M, Tominaga T

    Journal of neurological surgery. Part A, Central European neurosurgery 2022; (83(4)):391-395 doi:10.1055/s-0040-1722195.

    PMID: 33618408
  18. 18

    Prognostic Factors for Recurrence in Pituitary Adenomas: Recent Progress and Future Directions.

    Lu L, Wan X, Xu Y, et al.

    Diagnostics (Basel, Switzerland) 2022; (12(4)) doi:10.3390/diagnostics12040977.

    PMID: 35454025
  19. 19

    Genetic testing in pituitary adenomas: a Pituitary Society International Consensus Statement.

    De Sousa SMC, Andoniadou CL, Daly AF, et al.

    Nature reviews. Endocrinology 2026; doi:10.1038/s41574-026-01291-4.

    PMID: 42642458

This page explains how AIP-mutated pituitary tumors are evaluated for educational purposes only and is not medical advice. Your endocrinology, imaging, and pathology teams should interpret your results and plan follow-up.